Raptor Pharmaceuticals Provides Update of Produc...(theseforward-looking statements. Factors...),Health

Date:9/13/2007

these forward-looking statements. Factors which may significantly change or prevent the Company's forward looking statements from fruition include that the Company may be unsuccessful in developing any products; that its technology may not be validated as the Company progresses further and its methods may not be accepted by the scientific community; that the Company is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that the Company's patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; that the Company's products may not work as well as hoped or worse, that the Company's products may harm recipients; and that the Company may not be able to raise sufficient funds for development or working capital when required. As well, the Company's products may never develop into useful products and even if they do, they may not be approved for sale to the public. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the Securities and Exchange Commission ("SEC"), which we strongly urge you to read and consider, including the Company's Registration Statement on Form SB-2, as amended, that was declared effective on July 10, 2006, the Company's annual report on Form 10- KSB and Form 10-KSB/A filed with the SEC on November 22, 2006, and January 18, 2007, respectively, and the Company's quarterly report Form 10-QSB filed with the SEC on June 29, 2007, all of which are available free of charge on the SEC's web site at http://www.sec.gov.

Subsequent written and oral forward-looking statements attributable to t
'/>"/>

SOURCE Raptor Pharmaceuticals Corp. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia